3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Thyroid Cancer, Papillary
1
Polycystic Ovary Syndrome
1
Infertility
1
Head and Neck Neoplasms
1
Adenocarcinoma, Follicular
1
Interventions
Magnetic Resonance Spectroscopy
8
Iodine-131
8
Thyrotropin Alfa
5
trametinib
3
lenvatinib
3
cabozantinib
3
Sunitinib
3
Specimen Handling
3
Fluorodeoxyglucose F18
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
vandetanib
2
dabrafenib
2
X-Rays
2
Trastuzumab
2
Sorafenib
2
Rosiglitazone
2
Radiotherapy
2
Interviews as Topic
2
Gefitinib
2
Everolimus
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tremelimumab
1
tipifarnib
1
tanespimycin
1
spartalizumab
1
selpercatinib
1
sargramostim
1
romidepsin
1
pembrolizumab
1
pazopanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Adenocarcinoma, Follicular
×
Thyrotropin
×
Clear all
NCT00415233
2023-12-19
HiLo
University College, London
Phase 3
Unknown
438 enrolled